Key insights
- Organon's stock price jumped 15% following reports of a $12 billion takeover bid by Sun Pharmaceutical. While positive for Organon shareholders, the broader US market impact is limited. The deal highlights ongoing consolidation in the pharmaceutical sector, but it's unlikely to trigger widespread sector-wide movements.
%3Amax_bytes(150000)%3Astrip_icc()%2FGettyImages-2247416214-8880fa04a039401ebab136041845fce6.jpg&w=3840&q=75)
Organon shares are popping Friday on signs of a takeover deal.
Shares of the women's healthcare were recently 15% higher premarket following a report that India's Sun Pharmaceutical Industries submitted a binding offer to take over the Jersey City, N.J.-based firm. Shares of Organon entered the day down roughly 3.5% this year and were off some 40% over the past 12 months.
Organon (OGN) rose after Indian publication The Economic Times, citing "people in the know," said that Sun "has decided to proceed with a binding offer of $12 billion" for Organon. Organon has a market value near $2 billion, according to Visible Alpha, and an enterprise value above $9 billion.
Organon did not respond to Investopedia's request for comment in time for publication.
The Times said the offer brings Sun Pharmaceutical "to the final stages of its most ambitious overseas acquisition bid as it looks to become a branded and innovative drug-making powerhouse."
Organon in February reported 2025 revenue of over 6% billion, down 3% year-over-year, and projected similar sales this year.